SUPPLEMENTARY FIGURES

Association of Epstein-Barr virus serological reactivation with transitioning to systemic lupus erythematosus in at risk individuals

Neelakshi R. Jog¹, Kendra A. Young², Melissa E. Munroe¹, Michael T. Harmon¹, Joel M. Guthridge¹, Jennifer A. Kelly ¹, Diane L. Kamen³, Gary S. Gilkeson³, Michael H. Weisman⁴, David R. Karp⁵, Patrick M. Gaffney ¹, John B. Harley ⁶,⁷,⁸, Daniel J. Wallace⁴, Jill M. Norris², Judith A. James¹,⁹

¹Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA

²Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

³Department of Medicine, Medical University of South Carolina (MUSC), Charleston, SC, USA

⁴Division of Rheumatology, Cedar-Sinai Medical Center, Los Angeles, CA, USA

⁵Division of Rheumatic Diseases, University of Texas Southwestern Medical Center, Dallas, TX, USA

⁶Center of Autoimmune Genomics and Etiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, USA

⁷Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA

⁸US Department of Veterans Affairs Medical Center, Cincinnati, OH, USA

⁹Departments of Medicine and Pathology, University of Oklahoma Health Science Center, Oklahoma City, OK, USA

Correspondence: Judith A. James, MD, PhD. Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, 825 NE 13th Street, Oklahoma City, OK 73104, Phone: 405-271-4987, Fax: (405) 271-7063, Email: judith-james@omrf.org

Short title: EBV sero-reactivation in lupus transition
Figure S1. Relatives who subsequently transitioned to SLE had similar levels of total IgG as baseline compared to those who did not transition. Total IgG levels in serum were measured by ELISA at the baseline visit. A. Total IgG levels in relatives who transitioned to SLE (Transition, n=55) and matched relatives who did not transition to SLE (Non-Transition, n=94). B. Relatives who did not transition were divided based on ANA positivity status into ANA+ (n=47) and ANA- (n=47). Data are represented as median ± 95% CI. *p<0.05 by Mann Whitney.
Figure S2. Relatives who transitioned to classified SLE had similar levels of VZV IgG compared to relatives who did not transition and unrelated controls. IgG responses towards Varicella zoster (VZV IgG) were measured by ELISA. A. VZV IgG levels at baseline in relatives who transitioned to SLE (Transition, n=55), matched relatives who did not transition to SLE (Non-Transition, n=94), and unaffected unrelated controls (Control n=47). B. into ANA+ (n=47) and ANA- (n=47). Data are represented as median ± 95% CI. p>0.05 by Mann-Whitney.